Cancer

First Opinion

Cartoons offer a peek into cancer immunotherapy — and scientists’ minds

By Neil Canavan

Mammography screening Program
First Opinion

A widely used guideline said I didn’t need a mammogram. It was wrong

By Leda Dederich

The Readout LOUD

LISTEN: Fake friends at the FDA, cancer counter-narratives, and biotech’s bear turn

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Acute Promyelocytic Leukemia
Biotech

Early blood cancer trial is shuttered, possibly dimming hopes for promising therapy

By Damian Garde

Human cancer cells in culture
First Opinion

Drug sensitivity and resistance testing could make ‘right to try’ a real thing

By Joe Olechno

Gardasil
Health

FDA expands use of an HPV vaccine up to age 45

By Associated Press

Assasin within First Opinion illustration
First Opinion

Male doctors said my ‘female’ cancer was incurable. Then a woman took command and gave me hope

By Doreen Carvajal

Network connections
First Opinion

Precision medicine needs a business mindset in order to flourish

By Richard G. Hamermesh and Kathy E. Giusti

Steven Petrow
First Opinion

Memorial Sloan Kettering, you’ve betrayed my trust

By Steven Petrow

EPA Radiation Rollback
Health

Experts say Trump’s EPA is moving to loosen radiation limits

By Associated Press

Cancer Chemotherapy
Pharmalot

Cancer trials that rely on surrogate endpoints overlook quality-of-life issues

By Ed Silverman

James Allison Nobel Prize press conf.
In the Lab

The snub club: Crucial contributors to cancer immunotherapy were excluded from the medicine Nobel

By Sharon Begley

Padmanee Sharma
Heavyweights

A pioneer in cancer immunotherapy sees a future where vaccines, CAR-T, and checkpoint inhibitors come together

By Sharon Begley

Precusor B-cell Acute Lymphoblastic Leukemia
In the Lab

In rare case, patient developed resistance to CAR-T after cancer cell began hiding in ‘plain sight’

By Andrew Joseph

Nobel Medicine 2018
In the Lab

Nobel Prize in medicine awarded to two cancer researchers for immune system breakthrough

By Sharon Begley

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Cologuard
First Opinion

Colorectal cancer screening: Science should trump convenience

By Naresh Gunaratnam

Metastatic Melanoma Cells
Adam's Take

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By Adam Feuerstein

Jerome Adams with Trump and Melania
Health

Expanding addiction treatment, embracing the bully pulpit: Jerome Adams on his first year as surgeon general

By Andrew Joseph

Thomas Goode
Special Report

Denied ‘life-extending opportunities’: Black patients are being left out of clinical trials amid wave of new cancer therapies

By Caroline Chen and Riley Wong — ProPublica

Fancy cocktails
Politics

In response to critic, NIH alcoholism institute changes online explanation of cancer risk from drinking

By Sharon Begley

Wine toast
Health

Health researcher calls on NIH to retract statement about alcohol and cancer risk

By Sharon Begley

BRCA1 protein
Health

Study cracks open the secrets of the cancer-causing BRCA1 gene

By Sharon Begley

p53 CRISPR illo
In the Lab

That alarm about the cancer risks of CRISPR? It’s still ringing

By Sharon Begley

Genetic Frontiers Living Cancer Drugs
Biotech

What’s next for CAR-T and TCR? Five biotech execs on the lofty goals, the scientific challenges, and the looming price questions

By Kate Sheridan

Prostate Cancer
In the Lab

After cancer spreads, a single drug should work against all the tumors, study suggests

By Sharon Begley

Driver app
Business

With big-name backing, a startup launches to match cancer patients with clinical trials

By Rebecca Robbins

Adam Hayden
Health

Not if but when: After a diagnosis of brain cancer, a young dad and his family grapple with the uncertain time he has left

By Andrew Joseph

Chi Med lab
Biotech

China is poised to approve its first innovative homegrown drug for a common cancer. Next stop? The U.S.

By Rebecca Robbins

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy